HomeNDC LookupIngredientsPrednisolone Acetate › 61314-0637-15
Prednisolone Acetate 10 mg/mL Suspension/ Drops — NDC 61314-0637-15 package photo

Prednisolone Acetate 10 mg/mL Suspension/ Drops

by Sandoz Inc · 1 BOTTLE, PLASTIC in 1 CARTON (61314-637-15) / 15 mL in 1 BOTTLE, PLASTIC
NDC 61314-0637-15
🏷️ FDA NDC (as labeled) 61314-637-15 billing pads the product segment with a zero
This package
Contains15 mL in 1 bottle, plastic Cost per mL$4.39 NADAC Per package$65.91 / 15 ml Pack sizes3 compare ↓
Also priced by: Medicaid pays $5.13/unit · Part D plans $5.35/unit — full pricing hub ↓
Rx only Brand On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Prednisolone Acetate (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Jun 4, 2026 — Presence of Foreign Substance (Lupin Pharmaceuticals Inc.) · FDA recall D-0655-2026
Class III · May 18, 2026 — Failed Stability Specifications (AbbVie Inc.) · FDA recall D-0551-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
Past resolved recalls for this product (1)
Class II · Apr 13, 2022 · Terminated — cGMP deviations: Temperature abuse (Mckesson Medical-Surgical Inc. Corporate Office) · FDA recall D-1105-2022

🆔 Identity & classification

FDA NDC (as labeled) 61314-637-15
Product NDC 61314-637
11-digit billing NDC 61314063715
NCPDP billing unit ML — per mL (volume)
RxCUI 1376336
UNII 8B2807733D
Application # NDA017469
SPL Set ID 05d205c7-8f51-46b9-a6c5-4199bc432b26
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category NDA AUTHORIZED GENERIC
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1994-12-15
Route OPHTHALMIC
Dosage form SUSPENSION/ DROPS
Substance PREDNISOLONE ACETATE
GPI-14 86300050101815
GPI class prednisoLONE Acetate
GCN Seq No 007894
GCN 33153
HICL code 002870
Ingredient (HICL) Prednisolone Acetate
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6P
Therapeutic class — specific (HIC3) Eye Anti-Inflammatory Agents
AHFS code 52:08.08.00
AHFS class Corticosteroids (Eent)
FDB label name PREDNISOLONE AC 1% EYE DROP
FDB brand name Prednisolone Acetate
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AB · RLD · RS
Why two NDCs? The FDA registers this code as 61314-637-15 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 61314-0637-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids acting locally, Corticosteroids
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerSandoz Inc
Application holderSANDOZ INC
FDA applicationNDA017469 (NDA AUTHORIZED GENERIC)
Labeler code61314
First marketedDec 1994
Product typeHuman Prescription Drug
Portfolio387 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name PREDNISOLONE AC 1% EYE DROP Ingredient Prednisolone Acetate
📖 What it is MedlinePlus · NLM

Ophthalmic prednisolone reduces the irritation, redness, burning, and swelling of eye inflammation caused by chemicals, heat, radiation, infection, allergy, or foreign bodies in the eye. It sometimes is used after eye surgery. Prednisolone is in a class of medications called steroids. It prevents swelling and redness by changing the way the immune system works.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Prednisolone is a steroid that calms inflammation and dials down an overactive immune system. Depending on what you're being treated for — whether that's an asthma flare, a skin co...
  • Why has my doctor prescribed prednisolone — what is it actually doing?
  • Please don't stop on your own — this is one of the most important things to know about prednisolone. When you take it for more than a short time, your adrenal glands slow down thei...
  • Can I stop taking prednisolone when I start feeling better?
📖 Read our full Prednisolone guide →
8
Nutrient depletion considerations

Prednisolone may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII 2968PHW8QP
    A weak organic acid derived from citrus fruits or made through fermentation. It works as a buffer to control pH, a preservative to extend shelf life, and a flavoring agent in medications.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII 3NXW29V3WO
    Hypromellose is a plant-based thickener made from cellulose. It's used in medicines as a binder to hold ingredients together, a coating for tablets, and a thickener for liquids.
  • UNII 6OZP39ZG8H
    Polysorbate 80 is a synthetic emulsifier derived from sorbitol and oleic acid. It helps mix oil and water-based ingredients together in medications and improves how the product disperses in the body.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII GR686LBA74
    Sodium phosphate, dibasic is a salt derived from phosphoric acid. It acts as a buffer to help maintain the medicine's pH balance and may serve as a binder or filler in tablets and capsules.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

9 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $4.394 $65.91 / 15 ml
Medicaid paysCMS SDUD · 12 mo $5.13 $76.89 / 15 ml
Medicare drug plans payPart D · Q2 2026 $5.35 $80.18 / 15 ml
NADAC price history (per mL) — tap or hover for the price & month
Dec 2021 Jul 2022 Dec 2025 Aug 2026 $6.061 $3.652
▼ Down 21% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
prednisolone acetate 10 mg/mL 60219-2552-01 Amneal 1 bottle $4.394 AB Availability likely
Prednisolone Acetate 10 mg/mLthis 61314-0637-15 Sandoz 1 bottle $4.394 AB Availability likely
prednisolone acetate 10 mg/mL 60219-2551-01 Amneal 1 bottle $4.450 AB Availability likely +1%
prednisolone acetate 10 mg/mL 60219-2550-01 Amneal 1 bottle $4.589 AB Availability likely +4%
Prednisolone Acetate 10 mg/mL 60758-0119-05 Pacific 1 bottle $4.589 AB Availability likely +4%
Prednisolone Acetate 10 mg/mL 70748-0332-02 Lupin 1 bottle $4.589 AB Availability likely +4%
Pred Forte 10 mg/mL 11980-0180-01 Allergan, 1 bottle AB Discontinued
Prednisolone Acetate 10 mg/mL 50090-0559-00 A-S 1 bottle AB FDA listed
Prednisolone Acetate 10 mg/mL 50090-1912-00 A-S 1 bottle AB FDA listed
Prednisolone Acetate 10 mg/mL 50090-5275-00 A-S 1 bottle AB FDA listed
Prednisolone Acetate 10 mg/mL 50090-7539-00 A-S 1 bottle AB FDA listed
Prednisolone Acetate 10 mg/mL 67296-2176-05 Redpharm 1 bottle AB FDA listed
Prednisolone Acetate 10 mg/mL 68071-2222-05 NuCare 1 bottle AB FDA listed
Prednisolone Acetate 10 mg/mL 76420-0204-05 Asclemed 1 bottle AB FDA listed
Prednisolone Acetate 10 mg/mL 85766-0124-05 Sportpharm 1 bottle AB FDA listed
Prednisolone Acetate 10 mg/mL 85766-0258-05 Sportpharm 1 bottle AB FDA listed
About this product: this is an authorized generic — the brand-name product marketed without its brand name. Other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1994
On the market since
Dec 1994
📍
2026
Currently FDA-listed
32 years listed
🔓
·
Generic versions listed
see equivalents
Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 61314-0637-15, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
7.8K
Units reimbursed last 4 qtrs
116.4K
Gross reimbursed last 4 qtrs
$596.6K
Avg / prescription
$76.85
Avg / unit
$5.1258
Latest quarter Q4 2025
1.7KRx
Medicaid pays / mL
$5.1258
gross reimbursed
vs
NADAC / mL
$4.3937
acquisition cost
=
Spread
+$0.7321
+17% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
73% FFS 27% MCO
Fee-for-service · 5,671 Rx Managed care · 2,092 Rx
State Medicaid map
Alaska: no data reported AK Maine: 195 units · 14.0 per 100k residents ME Washington: 375 units · 4.8 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 780 units · 13.6 per 100k residents MN Wisconsin: 1,490 units · 25.2 per 100k residents WI Michigan: 3,710 units · 37.0 per 100k residents MI New York: 62,010 units · 317 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 840 units · 26.2 per 100k residents IA Illinois: 4,320 units · 34.4 per 100k residents IL Indiana: 180 units · 2.6 per 100k residents IN Ohio: 1,830 units · 15.5 per 100k residents OH Pennsylvania: 2,455 units · 18.9 per 100k residents PA New Jersey: 360 units · 3.9 per 100k residents NJ Massachusetts: no data reported MA California: 15,930 units · 40.9 per 100k residents CA Utah: no data reported UT Colorado: 585 units · 10.0 per 100k residents CO Nebraska: no data reported NE Missouri: 1,350 units · 21.8 per 100k residents MO Kentucky: 2,355 units · 52.0 per 100k residents KY West Virginia: no data reported WV Virginia: 845 units · 9.7 per 100k residents VA Maryland: 845 units · 13.7 per 100k residents MD Connecticut: 1,650 units · 45.6 per 100k residents CT Rhode Island: no data reported RI Arizona: 390 units · 5.2 per 100k residents AZ New Mexico: 195 units · 9.2 per 100k residents NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 1,140 units · 16.0 per 100k residents TN North Carolina: 1,844 units · 17.0 per 100k residents NC South Carolina: 195 units · 3.6 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 2,970 units · 64.9 per 100k residents LA Mississippi: no data reported MS Alabama: 925 units · 18.1 per 100k residents AL Georgia: 790 units · 7.2 per 100k residents GA D.C.: 235 units · 34.6 per 100k residents DC Hawaii: no data reported HI Texas: 3,885 units · 12.7 per 100k residents TX Florida: 1,710 units · 7.6 per 100k residents FL
Units reimbursed · per 100k residents
2.6317
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 317 /100k
2 Louisiana 64.9 /100k
3 Kentucky 52.0 /100k
4 Connecticut 45.6 /100k
5 California 40.9 /100k
6 Michigan 37.0 /100k
7 D.C. 34.6 /100k
8 Illinois 34.4 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 bottle61314-0637-05 161,496 Rx · $5,754,393
1 bottle61314-0637-10 28,142 Rx · $1,528,335
1 bottle this page61314-0637-15 7,763 Rx · $596,564
Drug total (last 4 qtrs): 197,401 Rx · 1,326,385 units · $7,879,291 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Prednisolone Acetate — the program that covers self-administered drugs. 4 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Prednisolone Acetate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$32.35M
Claims incl. refills
962.7K
Beneficiaries
744.7K
Spend / beneficiary
$43.45
Spend / claim
$33.61
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Prednisolone Acetate — the ingredient across all brands.

Top reported reactions

Treatment Failure1,264
Eye Pain722
Vision Blurred403
Eye Irritation392
Fatigue375
Headache363
Ocular Hyperaemia301

Reporter sex

0 reports
Male · 39%
Female · 60%
Unknown · 0%

Serious outcomes

Death552
Disabling325
Life-threatening268
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,792 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
61314-0637-05 1 BOTTLE, PLASTIC in 1 CARTON (61314-637-05) / 5 mL in 1 BOTTLE, PLASTIC $4.59 / mL $22.94 1994-12-15 Active
61314-0637-10 1 BOTTLE, PLASTIC in 1 CARTON (61314-637-10) / 10 mL in 1 BOTTLE, PLASTIC $4.45 / mL $44.50 1994-12-15 Active
61314-0637-15 You're viewing this 1 BOTTLE, PLASTIC in 1 CARTON (61314-637-15) / 15 mL in 1 BOTTLE, PLASTIC $4.39 / mL $65.91 1994-12-15 Active

This pack has the lowest per-mL cost of the 3 priced pack sizes ($4.39 NADAC).

This pack accounts for about 3.9% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in NDC 61314-0637-15?
NDC 61314-0637-15 is listed by the FDA — 1 bottle, plastic in 1 carton / 15 ml in 1 bottle, plastic.
What NDC number is used to bill for this package of Prednisolone Acetate 10 mg/mL Suspension/ Drops?
Bill NDC 61314-0637-15 — the 11-digit billing format is 61314063715. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 68 words

INDICATIONS AND USAGE: Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

⏱️ Dosage and Administration 94 words

DOSAGE AND ADMINISTRATION: SHAKE WELL BEFORE USING . Two drops topically in the affected eye(s) four times daily. In cases of bacterial infections, concomitant use of anti-infective agents is mandatory.

Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be reevaluated (see PRECAUTIONS ). The dosing of prednisolone acetate ophthalmic suspension may be reduced, but care should be taken not to discontinue therapy prematurely.

In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.

Contraindications 66 words

CONTRAINDICATIONS: Prednisolone acetate ophthalmic suspension is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Prednisolone acetate ophthalmic suspension is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

⚠️ Warnings ~1 min read

WARNINGS: FOR TOPICAL OPHTHALMIC USE. Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections.

Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. Acute purulent infections of the eye may be masked or activity enhanced by the presence of corticosteroid medication.

If this product is used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of glaucoma. IOP should be checked frequently.

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended.

Corticosteroids are not effective in mustard gas keratitis and Sjogren's keratoconjunctivitis.

🤒 Adverse Reactions 169 words

ADVERSE REACTIONS: Adverse reactions include, in decreasing order of frequency, elevation of IOP with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. Although systemic effects are extremely uncommon, there have been rare occurrences of systemic hypercorticoidism after use of topical steroids. Corticosteroid-containing preparations have also been reported to cause acute anterior uveitis and perforation of the globe.

Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. The development of secondary ocular infection (bacterial, fungal and viral) has occurred. Fungal and viral infections of the cornea are particularly prone to develop coincidentally with long-term applications of steroid.

The possibility of fungal invasion should be considered in any persistent corneal ulceration where steroid treatment has been used (see WARNINGS ). The following additional adverse reactions have been reported with prednisolone use: Cushing’s syndrome and adrenal suppression may occur after very frequent use of ophthalmic prednisolone, particularly in very young children.

🤰 Pregnancy 1 words

Pregnancy:

🧒 Pediatric Use 12 words

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

🧓 Geriatric Use 17 words

Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.

🧬 Clinical Pharmacology 122 words

CLINICAL PHARMACOLOGY: Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids.

However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Corticosteroids are capable of producing a rise in intraocular pressure.

📦 How Supplied / Storage and Handling 103 words

HOW SUPPLIED: Prednisolone acetate ophthalmic suspension is supplied in a white, round low density polyethylene dispenser with a natural low density polyethylene dispensing plug and pink polypropylene cap. Tamper evidence is provided with a shrink band around the closure and neck area of the package. Prednisolone Acetate Suspension, USP, 1%: 5 mL NDC 61314-637-05 10 mL NDC 61314-637-10 15 mL NDC 61314-637-15 STORAGE: Store at 8°C to 24°C (46°F to 75°F) in an UPRIGHT position.

After opening, prednisolone acetate ophthalmic suspension can be used until the expiration date on the bottle. Rx Only Distributed by Sandoz Inc. Princeton, NJ 08540 Rev.

Dec 2024

📋 Description 73 words

DESCRIPTION: Prednisolone acetate ophthalmic suspension is an adrenocortical steroid product prepared as sterile ophthalmic suspension for topical ophthalmic use. The active ingredient is represented by the chemical structure: Established name: Prednisolone Acetate Chemical name: Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-,(11β)-. Each mL contains: Active : prednisolone acetate 1.0%.

Preservative : benzalkonium chloride 0.01%. Inactives: citric acid monohydrate (to adjust pH), dibasic sodium phosphate, edetate disodium, glycerin, hypromellose, polysorbate 80, purified water, sodium hydroxide (to adjust pH). chemical

💬 Information for Patients 84 words

Information for Patients: If inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician. This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface.

The use of this bottle by more than one person may spread infection. Keep bottle tightly closed when not in use. Keep out of the reach of children.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.